Recently, ABCC3 has been included in gene signatures (ABCC3, CD44, TNFRSF1A, and MGMT24; ABCC3, SMC4, EMP3, WEE1, and HIST1H2BK44) that classify glioma patients in agreement with therapeutic response to chemotherapeutic agents, including TMZ. This evidence concerns the gene SMC4 and central nervous system cancer.